论著-头颈部
MRI结合肿瘤标志物在诊断前列腺癌中的应用
作者:张彦君1 丁德刚2 赵卫华3
所属单位:1.郑州煤炭工业(集团)有限责任公司总医院泌尿外科(河南 新密 452371) 2.河南省人民医院泌尿外科(河南 郑州 450000) 3.郑州煤炭工业(集团)有限责任公司总医院影像科(河南 新密 452371)
PDF摘要
目的探究核磁共振成像(MRI) 结合肿瘤标志物在前列腺癌(PCa)诊断中 的临床应用效果。方法 回顾性分析86例 前列腺疾病患者临床资料,根据组织学 穿刺活检结果良恶性分为PCa组(n=35)与 良性前列腺增生(BPH)组(n=51)。所有患 者均接受MRI与血清前列腺特异抗原(PSA) 检测,比较两组患者PSA相关指标水平异 同,并分析单纯检测PSA、MRI及二者联 合检查诊断准确性差异。结果 两组患者 PSA相关指标水平均存在明显差异(P均 <0.05)。MRI联合PSA检测对PCa的诊断符 合率为93.02%(80/86),明显高于两种单 纯检测方法(P均<0.05)。结论 MRI结合 肿瘤标志物诊断PCa准确性较高,有良好 的临床应用前景。
Objective To explore the clinical application of magnetic resonance imaging (MRI) combined with tumor markers in the diagnosis of prostatic cancer (PCa). Methods The clinical data of 86 patients with prostatic cancer were analyzed retrospectively. According to the results of histological biopsy and benign and malignant condition, the patients were divided into PCa group (n=35) and benign prostatic hyperplasia (BPH) group (n=51). All patients were detected by MRI and serum prostate specific antigen (PSA), and the levels of PSA related indicators were compared between the two groups, and differences in diagnostic accuracy of simple PSA, or MRI detection and the two combination were analyzed. Results There were significant differences in the levels of PSA related indicators between the two groups (all P<0.05). The diagnostic coincidence rate of MRI combined with PSA was 93.02% (80/86) in the detection of PCa, which was significantly higher than that of the two simple detection methods (all P<0.05). Conclusion MRI combined with tumor markers has high accuracy in the diagnosis of PCa, and it has a good prospect in clinical application.
【关键词】核磁共振成像;肿瘤标志物; 前列腺癌
【中图分类号】R737.25
【文献标识码】A
【DOI】 10.3969/j.issn.1672- 5131.2018.07.037
前言
前列腺主要病变类型中,前列腺癌(PCa)与良性前列腺增生(BPH) 近年来发病率均呈现出持续增长趋势,二者治疗方法与预后效果差异 较大,但其早期症状均不典型,临床鉴别诊断难度较高。前列腺特异 抗原(PSA)是目前应用最为广泛的前列腺疾病筛查肿瘤标志物[1],但其 并非PCa细胞特异性抗原,需结合其他检查手段进行判定。核磁共振成 像(MRI)由于具备软组织分辨率高、无电离辐射、多参数成像等特点, 在前列腺疾病诊断方面应用效果已获得广泛认可[2]。基于此,本研究 旨在采用MRI提升PSA检测对PCa的诊断准确性,取得成果汇报如下。
中国CT和MRI杂志
第16卷, 第 7 期
2018年07月
相关文章